# Query Results

**Query:** new guidelines for report generators

**Timestamp:** 20251020_030019

**Top K:** 5

**Results Found:** 5

---

## Result 1

**Similarity Score:** 0.3620 | **Semantic:** 0.5171 | **Keyword:** 0.0000 | **Rerank:** -7.0914

**Source:** iba-chemin-du-cyclotron-3-1348-louvain-la-iba-dosimetry.md

**Chunk ID:** 9

**Content:**

```
en/embed/generator/type_selection/47412652) [ Report ](https://www.yumpu.com/en/document/inappropriate/47412652 "Report as Inappropriate")
# IBA Chemin du Cyclotron, 3 | 1348 Louvain-la. - IBA Dosimetry 
IBA Chemin du Cyclotron, 3 | 1348 Louvain-la. - IBA Dosimetry 
IBA Chemin du Cyclotron, 3 | 1348 Louvain-la. - IBA Dosimetry 
SHOW MORE 
SHOW LESS 
[ ePAPER READ ](https://www.yumpu.com/en/document/read/47412652/iba-chemin-du-cyclotron-3-1348-louvain-la-iba-dosimetry "READ")
[ DOWNLOAD ePAPER ](
```

---

## Result 2

**Similarity Score:** 0.3670 | **Semantic:** 0.5243 | **Keyword:** 0.0000 | **Rerank:** -7.7341

**Source:** iba-reports-solid-full-year-2024-results-iba-group.md

**Chunk ID:** 28

**Content:**

```
nref1) Following a review into revenue recognition treatment of third-party equipment under IFRS15, revenue is now recognized at the full sales price of third-party equipment. As a result of this change, there is an increase in both reported revenue and cost of goods, with a decrease in gross margin (with overall gross profit remaining the same). FY24 numbers reflect this new method of reporting and FY23 numbers have been restated.
```

---

## Result 3

**Similarity Score:** 0.3853 | **Semantic:** 0.5504 | **Keyword:** 0.0000 | **Rerank:** -8.0624

**Source:** iba-reports-solid-full-year-2024-results-iba-group.md

**Chunk ID:** 19

**Content:**

```
* **New segment reporting** following updated organization structure in **three focused entities:** IBA Clinical, IBA Technologies and IBA Corporate. New reporting will be applied as of 2025 with 2024 pro-forma available in Section III

* **CFO transition:** Henri de Romree, Deputy CEO, appointed interim CFO following the departure of Soumya Chandramouli
```

---

## Result 4

**Similarity Score:** 0.3695 | **Semantic:** 0.5279 | **Keyword:** 0.0000 | **Rerank:** -10.0488

**Source:** iba-venture-pantera-gains-134m-in-funding-to-scale-up-actinium-225-production-pharmaceutical-technol.md

**Chunk ID:** 46

**Content:**

```
4-334096&utm_campaign=recommended-reports-nonlgp)
 * [![ReportsLogo](https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/img/placeholder_purple.gif)](https://www.pharmaceutical-technology.com/news/iba-venture-pantera-gains-e134m-in-funding-to-scale-up-actinium-225-production/)
[Reports ](https://www.globaldata.com/store/report/)
#### [LOA and PTSR Model - FPI-2059 in Gastric Cancer ](https://www.globaldata.com/store/report/fpi-2059-in-gastric-cancer-loa-and-ptsr-dr
```

---

## Result 5

**Similarity Score:** 0.3836 | **Semantic:** 0.5301 | **Keyword:** 0.0417 | **Rerank:** -10.4255

**Source:** awards-and-accolades-department-of-physics-and-nanotechnology-srmist.md

**Chunk ID:** 117

**Content:**

```
atory Disclosures ](https://webstor.srmist.edu.in/web_assets/downloads/2025/flipbook/aicte-mandate-disclosure/)
 * [ UGC guidelines ](https://www.ugc.gov.in/publication/ebook)
```

---

